Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company ...

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

Paris: Sanofi has announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded ...

Sanofi has agreed to acquire Vigil Neuroscience in a cash transaction with an equity... DUBLIN The Iseq All Share opened in the red on Thursday, falling 0.34 per cent (-39.24bps)... Jakob Stausholm, ...

Many of those employees have been working there since March, the majority transferred from a former Sanofi location in ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

Global healthcare company Sanofi yesterday formally opened its new flagship US offices at M Station West in Morristown.

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...